Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.

Beylergil V, Morris PG, Smith-Jones PM, Modi S, Solit D, Hudis CA, Lu Y, O'Donoghue J, Lyashchenko SK, Carrasquillo JA, Larson SM, Akhurst TJ.

Nucl Med Commun. 2013 Dec;34(12):1157-65. doi: 10.1097/MNM.0b013e328365d99b.

2.

Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.

Mortimer JE, Bading JR, Colcher DM, Conti PS, Frankel PH, Carroll MI, Tong S, Poku E, Miles JK, Shively JE, Raubitschek AA.

J Nucl Med. 2014 Jan;55(1):23-9. doi: 10.2967/jnumed.113.122630.

3.

64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.

Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, Honda N, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Hasegawa K, Kanayama Y, Nozaki S, Kinoshita T, Wada Y, Tazawa S, Takahashi K, Watanabe Y, Fujiwara Y.

J Nucl Med. 2013 Nov;54(11):1869-75. doi: 10.2967/jnumed.112.118612.

4.

Considerations on absence of 68Ga-DOTA-F(ab')2-trastuzumab tracer uptake in HER2-overexpressing tumor lesions.

Oude Munnink TH, Brouwers AH, de Vries EG.

Nucl Med Commun. 2014 Jul;35(7):785-6. doi: 10.1097/MNM.0000000000000123. No abstract available.

PMID:
24878883
5.

Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.

Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T.

J Nucl Med. 2016 Jan;57(1):27-33. doi: 10.2967/jnumed.115.162024.

PMID:
26449837
6.

Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.

Oude Munnink TH, de Vries EG, Vedelaar SR, Timmer-Bosscha H, Schröder CP, Brouwers AH, Lub-de Hooge MN.

Mol Pharm. 2012 Nov 5;9(11):2995-3002. doi: 10.1021/mp3002182.

PMID:
23003202
7.

68Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-synthetic HER2 specific Affibody ZHER2:342-pep2.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Aug 26 [updated 2010 Nov 10].

8.

68Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-HER2-specific Affibody ZHER2:2891.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Aug 26 [updated 2012 Dec 12].

9.

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A.

Lancet Oncol. 2014 Dec;15(13):1493-502. doi: 10.1016/S1470-2045(14)70475-9.

PMID:
25456368
10.

Molecular imaging reveals trastuzumab-induced epidermal growth factor receptor downregulation in vivo.

Ma T, Sun X, Cui L, Gao L, Wu Y, Liu H, Zhu Z, Wang F, Liu Z.

J Nucl Med. 2014 Jun;55(6):1002-7. doi: 10.2967/jnumed.114.137000.

11.

First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.

Sörensen J, Sandberg D, Sandström M, Wennborg A, Feldwisch J, Tolmachev V, Åström G, Lubberink M, Garske-Román U, Carlsson J, Lindman H.

J Nucl Med. 2014 May;55(5):730-5. doi: 10.2967/jnumed.113.131243.

12.

N-[2-(4-[18F]Fluorobenzamido)ethyl]maleimide-Cys-ZEGFR:1907.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Jul 31 [updated 2012 Nov 1].

14.

HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.

Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F.

Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1525-33. doi: 10.1007/s00259-014-2739-1.

PMID:
24647576
15.

Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments.

Holloway CM, Scollard DA, Caldwell CB, Ehrlich L, Kahn HJ, Reilly RM.

Nucl Med Biol. 2013 Jul;40(5):630-7. doi: 10.1016/j.nucmedbio.2013.03.005.

PMID:
23618841
16.

111In-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-AB.Fab4D5 .

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Apr 16 [updated 2007 Nov 8].

17.

64Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-human serum albumin-Ac-Cys-ZEGFR:1907.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Jun 25 [updated 2012 Sep 27].

18.

Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.

Xavier C, Vaneycken I, D'huyvetter M, Heemskerk J, Keyaerts M, Vincke C, Devoogdt N, Muyldermans S, Lahoutte T, Caveliers V.

J Nucl Med. 2013 May;54(5):776-84. doi: 10.2967/jnumed.112.111021.

19.

111In-Benzyl-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid-ZHER2:342.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2008 Apr 6 [updated 2008 May 29].

20.

Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.

Paudyal P, Paudyal B, Hanaoka H, Oriuchi N, Iida Y, Yoshioka H, Tominaga H, Watanabe S, Watanabe S, Ishioka NS, Endo K.

Cancer Sci. 2010 Apr;101(4):1045-50. doi: 10.1111/j.1349-7006.2010.01480.x.

Items per page

Supplemental Content

Support Center